Clinical trial / 2021
Nicotinamide mononucleotide supplementation combined with exercise enhanced aspects of aerobic capacity in amateur runners.
A 6-week randomized, double-blind, placebo-controlled trial evaluated 48 recreationally trained runners assigned to placebo or 300, 600, or 1200 mg/day of nicotinamide mononucleotide (NMN) alongside 40-60 minute exercise sessions 5-6 times weekly. Oxygen uptake (VO2), percentages of VO2max, and power at both the first and second ventilatory thresholds increased to a higher degree in the medium and high dosage groups compared to control. However, there was no difference in VO2max, O2-pulse, VO2 related to work rate, or peak power after the 6-week treatment from baseline across any groups.
- Study type
- Randomized, double-blind, placebo-controlled, 4-arm clinical trial
- Who was studied
- 48 young and middle-aged recreationally trained runners (40 males, 8 females)
- What was measured
- Aerobic capacity via cardiopulmonary exercise testing
THE PAPER
Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.
Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. J Int Soc Sports Nutr, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.